Patient-reported outcomes (PROs) in NRG Oncology RTOG 0436

A phase III trial evaluating the addition of cetuximab to paclitaxel, cisplatin, and radiation for esophageal cancer treated without surgery

Bibliographic Data

ID15301666
AuthorsLisa A Kachnic (0000-0001-8239-9147, Morgan Stanley Children's Hospital, corresponding author), Kathryn Winter (NRG Oncology), Mohan Suntharalingam (University of Maryland, Baltimore), David H Ilson (0000-0003-0831-2247, Memorial Sloan Kettering Cancer Center), David Ilson, André Konski (0000-0002-6936-7682, University of Pennsylvania), Shane Lloyd (0000-0002-4235-7652, University of Utah), Sarah McAvoy (0000-0002-1114-4312, University of Maryland, Baltimore), Sarah A McAvoy, Thomas E Lad (John H. Stroger, Jr. Hospital of Cook County), Thomas Lad, Olugbenga Gbenga Olowokure (University of Cincinnati), Pamela Samson (Washington University in St. Louis), Elizabeth Gore (Medical College of Wisconsin), Elizabeth M Gore, Joshua E Meyer (0000-0002-7585-5738, Fox Chase Cancer Center), Gregory M M Videtic (0000-0002-6276-1505, Cleveland Clinic), David A Clump, Adam Raben (0009-0002-7148-2070, Christiana Care Health System), Omar Kayaleh (Orlando Health), Jerry L Barker (0000-0001-8700-4204, Texas Oncology), Jerry Barker, Michael G Haddock (0000-0001-8966-744X, Mayo Clinic in Arizona), Judith O Hopkins (0000-0002-9829-1242, Novant Health), Deborah Watkins Bruner (0000-0002-5770-9948, Emory University)
Year2024
Volume33
Issue10
Pages2833-2844
Publication date2024-07-27
Open AccessYes
TypeARTICLE
VenueQuality of Life Research (JOURNAL)
Journal identifiersISSN: 0962-9343 • E-ISSN: 1573-2649
PublisherSpringer Science+Business Media (PUBLISHER • DE)
DOI10.1007/s11136-024-03736-7
PMID39066879
OpenAlexW4401048927
LanguageEN
References cited25

Tools

Open DOIOpen Access